Can needle-free administration of vaccines become the norm in global immunization?

If vaccines could be administered without needles and syringes ('sharps'), immunization practice would become safer, more accepted and more suitable for mass use. The author explores the status of technologies that could achieve this aim and the barriers that must be overcome for their implementation.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1


  1. 1

    Aylward, B., Lloyd, J., Zaffran, M., McNair-Scott, R. & Evans, P. Reducing the risk of unsafe injections in immunization programmes: financial and operational implications of various injection technologies. Bull. World Health Org. 73, 531–540 (1995).

  2. 2

    Simonsen, L., Kane, A., Lloyd, J., Zaffran, M. & Kane, M. Unsafe injections in the developing world and transmission of bloodborne pathogens: a review. Bull. World Health Org. 77, 789–800 (1999).

  3. 3

    Levine, M.M. & Dougan, G. Optimism over vaccines administered via mucosal surfaces. Lancet 351, 1375–1376 (1998).

  4. 4

    Neutra, M.R., Frey, A. & Kraehenbuhl, J.P. Epithelial M cells: gateways for mucosal infection and immunization. Cell 86, 345–348 (1996).

  5. 5

    Levine, M.M. et al. Duration of efficacy of ty21a, attenuated Salmonella typhi live oral vaccine. Vaccine 17 (Suppl 2), S22–S27 (1999).

  6. 6

    Levine, M.M. & Kaper, J.B. Live oral cholera vaccine: from principle to product. Bull. Inst. Pasteur 93, 243–253 (1995).

  7. 7

    Sanchez, J.L. et al. Protective efficacy of oral whole-cell/recombinant-B-subunit cholera vaccine in Peruvian military recruits. Lancet 344, 1273–1276 (1994).

  8. 8

    Trach, D.D. et al. Field trial of a locally produced, killed, oral cholera vaccine in Vietnam. Lancet 349, 231–235 (1997).

  9. 9

    Murphy, T.V. et al. Intussusception among infants given an oral rotavirus vaccine. N. Engl. J. Med. 344, 564–572 (2001).

  10. 10

    John, T.J. & Jayabal, P. Oral polio vaccination of children in the tropics. I. The poor seroconversion rates and the absence of viral interference. Am. J. Epidemiol. 96, 263–269 (1972).

  11. 11

    Gotuzzo, E. et al. Safety, immunogenicity, and excretion pattern of single-dose live oral cholera vaccine CVD 103-HgR in Peruvian adults of high and low socioeconomic levels. Infect. Immun. 61, 3994–3997 (1993).

  12. 12

    Hanlon, P. et al. Trial of an attenuated bovine rotavirus vaccine (RIT 4237) in Gambian infants. Lancet 1, 1342–1345 (1987).

  13. 13

    Lagos, R. et al. Effect of small bowel bacterial overgrowth on the immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR. J. Infect. Dis. 180, 1709–1712 (1999).

  14. 14

    Cooper, P.J. et al. Albendazole treatment of children with ascariasis enhances the vibriocidal antibody response to the live attenuated oral cholera vaccine CVD 103-HgR. J. Infect. Dis. 182, 1199–1206 (2000).

  15. 15

    Pasetti, M.F., Anderson, R.J., Noriega, F.R., Levine, M.M. & Sztein, M.B. Attenuated deltaguaBA Salmonella typhi vaccine strain CVD 915 as a live vector utilizing prokaryotic or eukaryotic expression systems to deliver foreign antigens and elicit immune responses. Clin. Immunol. 92, 76–89 (1999).

  16. 16

    Tacket, C.O. et al. Safety and immune responses to attenuated Salmonella enterica serovar typhi oral live vector vaccines expressing tetanus toxin fragment C. Clin. Immunol. 97, 146–153 (2000).

  17. 17

    Tacket, C.O. et al. Immunogenicity in humans of a recombinant bacterial antigen delivered in a transgenic potato. Nature Med. 4, 607–609 (1998).

  18. 18

    Tacket, C.O. et al. Enteral immunization and challenge of volunteers given enterotoxigenic E. coli CFA/II encapsulated in biodegradable microspheres. Vaccine 12, 1270–1274 (1994).

  19. 19

    Belshe, R.B. et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine in children. N. Engl. J. Med. 338, 1405–1412 (1998).

  20. 20

    King, J.C., Jr. et al. Safety and immunogenicity of low and high doses of trivalent live cold- adapted influenza vaccine administered intranasally as drops or spray to healthy children. J. Infect. Dis. 177, 1394–1397 (1998).

  21. 21

    Levine, M., Kaper, J., Black, R.E. & Clements, M. New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development. Microbiol. Rev. 47, 510–550 (1983).

  22. 22

    Gluck, R. et al. Safety and immunogenicity of intranasally administered inactivated trivalent virosome-formulated influenza vaccine containing Escherichia coli heat-labile toxin as a mucosal adjuvant. J. Infect. Dis. 181, 1129–1132 (2000).

  23. 23

    Douce, G. et al. Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants. Proc. Natl. Acad. Sci. USA 92, 1644–1648 (1995).

  24. 24

    Yamamoto, S. et al. Mutants in the ADP-ribosyltransferase cleft of cholera toxin lack diarrheagenicity but retain adjuvanticity. J. Exp. Med. 185, 1203–1210 (1997).

  25. 25

    Van Ginkel, F.W., Jackson, R.J., Yuki, Y. & McGhee, J.R. Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J. Immunol. 165, 4778–4782 (2000).

  26. 26

    Agren, L.C., Ekman, L., Lowenadler, B., Nedrud, J.G. & Lycke, N.Y. Adjuvanticity of the cholera toxin A1-based gene fusion protein, CTA1-DD, is critically dependent on the ADP-ribosyltransferase and Ig-binding activity. J. Immunol. 162, 2432–2440 (1999).

  27. 27

    Dilraj, A. et al. Response to different measles vaccine strains given by aerosol and subcutaneous routes to schoolchildren: a randomised trial. Lancet 355, 798–803 (2000).

  28. 28

    Fernandez-de Castro, J., Kumate-Rodriguez, J., Sepulveda, J., Ramirez-Isunza, J.M. & Valdespino-Gomez, J.L. La vacunacion antisarampionosa en Mexico por el metodo de aerosol. Salud Publica Mex. 39, 53–60 (1997).

  29. 29

    Hingson, R.A., Davis, H.S. & Rosen, M. The historical development of jet injection and envisioned uses in mass immunization and mass therapy based upon two decades experience. Milit. Med. 128, 516–524 (1963).

  30. 30

    Canter, J. et al. An outbreak of hepatitis B associated with jet injections in a weight reduction clinic. Arch. Intern. Med 150, 1923–1927 (1990).

  31. 31

    Cohen Reis, E., Jacobsen, R.M., Tarbell, S. & Weniger, B.G. Taking the sting out of shots: control of vaccination-associated pain and adverse reactions. Pediatr. Ann. 27, 375–386 (1998).

  32. 32

    Jackson, L.A. et al. Safety and immunogenicity of varying dosages of trivalent inactivated influenza vaccine administered by needle-free jet injectors. Vaccine 19, 4703–4709 (2001).

  33. 33

    Jodar, L. et al. Ensuring vaccine safety in immunization programmes—a WHO perspective. Vaccine 19, 1594–1605 (2001).

  34. 34

    Parent du Chatelet, I. et al. Clinical immunogenicity and tolerance studies of liquid vaccines delivered by jet-injector and a new single-use cartridge (Imule): comparison with standard syringe injection. Imule Investigators Group. Vaccine 15, 449–458 (1997).

  35. 35

    Roy, M.J. et al. Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. Vaccine 19, 764–778 (2000).

  36. 36

    Glenn, G.M., Rao, M., Matyas, G.R. & Alving, C.R. Skin immunization made possible by cholera toxin. Nature 391, 851–851 (1998).

  37. 37

    Guerena-Burgueno, F. et al. Safety and immunogenicity of a prototype enterotoxigenic Escherichia coli vaccine administered transcutaneously. Infect. Immun. 70, 1874–1880 (2002).

  38. 38

    Mikszta, J.A. et al. Improved genetic immunization via micromechanical disruption of skin-barrier function and targeted epidermal delivery. Nature Med. 8, 415–419 (2002).

  39. 39

    Levine, M.M., Campbell, J.D. & Kotloff, K.L. Overview of vaccines and immunisation. Br. Med. Bull. 62, 1–13 (2002).

  40. 40

    Summary of the joint statement on thimerosal in vaccines. American Academy of Family Physicians, American Academy of Pediatrics, Advisory Committee on Immunization Practices, Public Health Service. MMWR Morb. Mortal. Wkly. Rep. 49, 622, 631 (2000).

Download references

Author information

Rights and permissions

Reprints and Permissions

About this article

Further reading